Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib

Andrew J Piper-Vallillo^{1

2

3}, Lecia V Sequist^{2

3}

Affiliations

Editorial

Andrew J Piper-Vallillo et al. JACC CardioOncol. 2019.

. 2019 Dec 17;1(2):179-181.

doi: 10.1016/j.jaccao.2019.11.011. eCollection 2019 Dec.

Andrew J Piper-Vallillo^{1

2

3}, Lecia V Sequist^{2

3}

No abstract available

Keywords: EGFR; NSCLC; cardiotoxicity; osimertinib.

Figures

1. Soria J.-C., Ohe Y., Vansteenkiste J. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2017;378:113–125. - PubMed
1. Mok T.S., Wu Y.-L., Ahn M.-J. AURA3 osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2016;376:629–640. - PMC - PubMed
1. Ramalingam S.S., Gray J.E., Ohe Y. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis (abstr) Ann Oncol. 2019;30 Suppl 5
1. Reungwetwattana T., Nakagawa K., Cho B.C. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer. J Clin Oncol. 2018;36:3290–3297. - PubMed
1. Anand K., Ensor J., Trachtenberg B., Bernicker E.H. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS) J Am Coll Cardiol CardioOnc. 2019;1:172–178. - PMC - PubMed